Diagnostic Lab Investment Opportunities in Wilmington

Business Highlights: - Founded 4 years ago, began with a COVID-19 experiment using 1,300 samples, achieving an impressive 99.77% accuracy compared to RT-PCR. - Intellectual property: Secured a patent grant, solidifying our innovative approach in AI-driven diagnostics. - Accelerator & industry recognition: Selected for The Roux Institute’s Future of Healthcare acceleration program, providing mentorship and strategic growth opportunities. - Non-dilutive & early investment traction: Gained momentum with multiple grants and secured a $50K pre-seed investment, fueling research and development. - E. coli study success: Conducted a preclinical study demonstrating 87% accuracy, further validating our RF-based pathogen detection technology. - Funding & resources: Currently leveraging USD 725K in total grants and credits, including K in USD 70 K grants received, USD 350K in Google Cloud credits, and an expected USD 305K SBIR grant from NSF. - Industry partnerships & market strategy: -- NorDx is set to be our first commercial client upon market entry. - Recognition & awards: -- Accepted into the Nvidia Inception Program for AI innovation. -- Runner-up in the AWS x Nvidia pitch competition in Austin, positioning business at the forefront of AI-powered diagnostics. - Market Launch & Revenue. - Fundraising progress: Raising USD 3M to commercialize, with USD 105K secured through SAFE notes and strong investor interest. - Business Model & Revenue Potential: Projected first-year revenue of USD 3M, with sales of 600 diagnostic units upon launch. Scalable B2B model targeting diagnostic labs, hospitals, and healthcare providers. - Potential for recurring revenue streams through AI-powered diagnostic subscriptions and consumables. - Regulatory & Clinical Traction for a Competitive Edge. Ongoing clinical validation and regulatory alignment with CLIA/CAP-accredited labs. RF-based diagnostics provide a faster, non-invasive alternative to traditional molecular testing. - With high asset valuation, driven by significant equipment costs, the company stands out in the diagnostics sector with its advanced technological infrastructure. - With a compact team of 6 skilled employees, the business emphasizes agility and innovation in its operations, facilitating quick progress in the fast-paced diagnostic technology sector.

Business Highlights: - Founded 4 years ago, began with a COVID-19 experiment using 1,300 samples, achieving an impressive 99.77% accuracy compared to RT-PCR. - Intellectual property: Secured a patent grant, solidifying our innovative approach in AI-driven diagnostics. - Accelerator & industry recognition: Selected for The Roux Institute’s Future of Healthcare acceleration program, providing mentorship and strategic growth opportunities. - Non-dilutive & early investment traction: Gained momentum with multiple grants and secured a $50K pre-seed investment, fueling research and development. - E. coli study success: Conducted a preclinical study demonstrating 87% accuracy, further validating our RF-based pathogen detection technology. - Funding & resources: Currently leveraging USD 725K in total grants and credits, including K in USD 70 K grants received, USD 350K in Google Cloud credits, and an expected USD 305K SBIR grant from NSF. - Industry partnerships & market strategy: -- NorDx is set to be our first commercial client upon market entry. - Recognition & awards: -- Accepted into the Nvidia Inception Program for AI innovation. -- Runner-up in the AWS x Nvidia pitch competition in Austin, positioning business at the forefront of AI-powered diagnostics. - Market Launch & Revenue. - Fundraising progress: Raising USD 3M to commercialize, with USD 105K secured through SAFE notes and strong investor interest. - Business Model & Revenue Potential: Projected first-year revenue of USD 3M, with sales of 600 diagnostic units upon launch. Scalable B2B model targeting diagnostic labs, hospitals, and healthcare providers. - Potential for recurring revenue streams through AI-powered diagnostic subscriptions and consumables. - Regulatory & Clinical Traction for a Competitive Edge. Ongoing clinical validation and regulatory alignment with CLIA/CAP-accredited labs. RF-based diagnostics provide a faster, non-invasive alternative to traditional molecular testing. - With high asset valuation, driven by significant equipment costs, the company stands out in the diagnostics sector with its advanced technological infrastructure. - With a compact team of 6 skilled employees, the business emphasizes agility and innovation in its operations, facilitating quick progress in the fast-paced diagnostic technology sector.